GLP weight-loss drug Ozempic has reportedly been linked to a rare form of vision loss, known as non-arteritic anterior ischemic optic neuropathy (NAION). The study, which has yet to be peer-reviewed, ...
For the first time in a decade, obesity in the U.S. is declining — and a new study suggests it’s because of wildly popular medications such as Ozempic.
Obesity dipped slightly in U.S. adults last year, research found — the first time in more than a decade that the country has ...
People taking Ozempic and Wegovy, which contain the drug semaglutide, may be at an increased risk of developing a ...
Novo Nordisk’s (NVO) blockbuster diabetes drug Ozempic may have a potential link with an eye condition that causes vision ...
Some people are not taking weight-loss medications responsibly, the physician says, and don't realize their full implications ...
NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...
6h
Semaglutide use in diabetes patients is linked to a higher risk of NAION, a rare eye condition. A Danish-Norwegian study ...
Over half of American adults are eligible for semaglutide, but insurance and other barriers make it hard for people to access ...
Popular GLP-1 medications like semaglutide in Ozempic and Wegovy help people lose weight, but what should patients know about ...
It’s quickly become evident that GLP-1 drugs for diabetes, weight loss, and more are the new wonder drugs—if only people ...
Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback